TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05210192
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection into the sphenopalatine ganglion of the patients in both groups will be made by entering the arcus zygomaticum and oriented at a 45 degree angle towards the opposite tooth. Injections will be made with a dental injector. The second group will be injected with 4ml of 0.9% saline. Injections will be repeated weekly for the first 4 weeks, then monthly. At the end of the 1st and 3rd months of the treatment, the patients will be evaluated in the routine outpatient clinic control, and the two groups will be compared statistically by questioning the frequency of pain, the number of attacks, the severity of pain (VAS), and the duration of pain.
Study: NCT05737082
Drug: HCP2201
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take 2 tablets once per period
Study: NCT05737082
Drug: RLD2205
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take 2 tablets once per period
Study: NCT05737082
Drug: RLD2206
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take 1 tablet once per period
Study: NCT05349045
Drug: an anti-PD-1/PD-L1 antibody plus an angiogenesis inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is an observational study
Study: NCT06670950
Drug: SYT-510
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral formulation A fasted
Study: NCT06670950
Drug: SYT-510
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral formulation B fasted
Study: NCT06670950
Drug: SYT-510
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral formulation A fed
Study: NCT06670950
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral formulation
Study: NCT06750627
Drug: Multimodal Intravenous Analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal intravenous analgesia refers to the use of multiple intravenous (IV) agents with different mechanisms of action to provide effective pain relief. The goal is to achieve synergistic effects that improve analgesia while minimizing the doses of individual drugs, thereby reducing side effects. This approach is often used in perioperative and acute pain management.~Patient will receive combinations of opioid through Patient Controlled Analgesia (PCA) device, NSAIDs, and Paracetamol (Acetaminophen)
Study: NCT06769152
Drug: HLX43 DOSE 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
Study: NCT06769152
Drug: HLX43 DOSE 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
Study: NCT06769152
Drug: HLX43 DOSE 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
Study: NCT04948099
Drug: VIB1116
Approvals — FDA: no, EMA: no, PMDA: no
Description: VIB1116
Study: NCT04948099
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06780930
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: For oral administration once daily
Study: NCT06775431
Drug: Pethidine Hydrochloride 50 Mg/mL Solution for Injection
Normalized name: Pethidine hydrochloride 50 mg/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pethidine will be administered intravenously in group A 0.5 mg/kg as premedication
Study: NCT06775431
Drug: Pethidine Hydrochloride 50 Mg/mL Solution for Injection administered intrathecally
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg pethidine in trathecally will be administered with bupivacaine 0.5% in group B
Study: NCT05619783
Drug: AMX0035
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 3 g phenylbutyrate and 1 g taurursodiol
Study: NCT05673785
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide IV infusion
Study: NCT05673785
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin IV infusion
Study: NCT06334016
Drug: Cannabis sativa Extract
Normalized name: Cannabis sativa whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vape THC
Study: NCT06777238
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT06509191
Drug: Intervention 1
Normalized name: DRESSING,QUIKCLOT INTERVENTION 1.5X1.5IN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 5mg/day
Study: NCT06391775
Drug: Standard Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV administration
Study: NCT05375851
Drug: Treatment as Usual
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: The usual treatment will be standardized as follows:~Biweekly online consultations (via WhatsApp or Google Meet) previously scheduled, 20/30 minutes-long, with a trained psychiatrist.~The patient will receive only clinical, not psychotherapeutic treatment. The psychiatrist will be instructed to perform an assessment of symptoms, general guidelines on the pathology, use of medication when necessary.~The medication of choice, when necessary, will be fluoxetine, as it is the medication for the treatment of GAD available free of charge in our health system in Brazil.
Study: NCT05169697
Drug: A:YH002+YH001
Approvals — FDA: no, EMA: no, PMDA: no
Description: YH002 on CnD1,YH001 on CnD8,Q3W
Study: NCT05169697
Drug: B:YH002+YH001
Approvals — FDA: no, EMA: no, PMDA: no
Description: YH002 and YH001 on same day,Q3W
Study: NCT05169697
Drug: YH002+YH001
Approvals — FDA: no, EMA: no, PMDA: no
Description: A traditional 3+3 dose escalation algorithm
Study: NCT06495372
Drug: control group (standard of care + placebo).
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard of care + placebo
Study: NCT06773936
Drug: Induction Phase
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asciminib, Dasatinib, Prednisone, and Methotrexate
Study: NCT06773936
Drug: Re-Induction Phase
Normalized name: Re-Covr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blinatumomab, Dasatinib, Methotrexate, and Dexamethasone
Study: NCT06759064
Drug: zoledronic acid plus Sintilimab intraperitoneal injection
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: At D-5\~D-1, drain the ascites by placing a tube in the abdominal cavity first, try to drain the ascites as much as possible according to the clinical routine, and record the amount of drainage.D1, D8, D15, D22 start the first immunocheckpoint inhibitor combined with zoledronic acid treatment, try to drain the ascites first, calculate the amount of drugs according to the patient's body weight, and then dissolve the corresponding dosage of immunocheckpoint inhibitor and zoledronic acid in 100 ml of saline and inject them into the abdominal cavity respectively, and then inject another 100 ml of saline according to the patient's tolerance. The corresponding dose of immune checkpoint inhibitor and zoledronic acid was dissolved in 100 ml of saline and injected into the abdominal cavity.
Study: NCT05386121
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given intravenously (1 µg/kg) as part of induction of general anesthesia (GA) added to propofol 2 mg/kg and atracurium 0.5 mg/kg Intraoperatively, intravenous fentanyl 0.5 µg/kg (with a maximum dose of 2 µg/kg) will be administered in response to any increase in hemodynamics by more than 20% of baseline values in response to skin incision or there after throughout surgery (after exclusion of other causes of hemodynamic changes)
Study: NCT06744868
Drug: Placebo of THDBH120 injection (SAD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received single dose of placebo by subcutaneous injection.
Study: NCT06744868
Drug: THDBH120 injection (MAD)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants received multiple doses of THDBH120 once weekly for four weeks by subcutaneous injection.
Study: NCT06744868
Drug: Placebo of THDBH120 injection (MAD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received placebo once weekly for four weeks by subcutaneous injection.
Study: NCT06740552
Drug: Lipid Lowering Medication
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any lipid lowering medication, including statin, ezetimibe, fibrates and etc.
Study: NCT06784661
Drug: Lipid-Based Artificial Tear
Approvals — FDA: no, EMA: no, PMDA: no
Description: This intervention consists of a lipid-based artificial tear formulation containing mineral oil and hydroxypropyl guar. It is designed to enhance the tear film's lipid layer and improve ocular surface stability. Participants in this group will receive a single drop in each eye, and corneal aberrations will be measured at baseline and 15 minutes after instillation.
Study: NCT06784661
Drug: Non-Lipid Artificial Tear
Approvals — FDA: no, EMA: no, PMDA: no
Description: This intervention consists of a non-lipid artificial tear formulation containing hydroxypropyl guar. It is intended to stabilize the aqueous layer of the tear film and maintain optical quality. Participants in this group will receive a single drop in each eye, and corneal aberrations will be measured at baseline and 15 minutes after instillation.
Study: NCT05699408
Drug: INS068 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: INS068 injected subcutaneously once daily. Treat-to-target dose titration during the trial
Study: NCT06732622
Drug: Steroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone as 5 mg tablets (Tianjin Lisheng Pharmaceutical Co., Ltd., China) were given as a single dose of 30 mg daily for the first 3 days; 15 mg daily for the following 3 days; 10 mg daily for the after 3 days; 5 mg daily for the final 3 days, with a total treatment time of 12 days.
Study: NCT06731959
Drug: Flexlamose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexlamose solution via nebulizer for 28 days
Study: NCT06731959
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution via nebulizer for 28 days
Study: NCT06118034
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take 0.5mg of starch tablets orally for 3 days before surgery, and continued to take 0.5mg every other day (qod) for 10 days after tracheal extubation.
Study: NCT05225415
Drug: CT1812
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered CT1812
Study: NCT06792955
Drug: HRS9531 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose pen of HRS9531 injection solution.
Study: NCT05996185
Drug: DA-EPOCH Protocol
Normalized name: Epoch Blemish
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPOCH is an intensive chemotherapy regimen intended for treatment of aggressive non-Hodgkin's lymphoma.
Study: NCT06577558
Drug: SR1375 capsule 0.3mg+regular treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR1375 capsule 0.3mg QD orally+CAP regular treatments
Study: NCT06577558
Drug: Placebo capsule+regular treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule QD orally+CAP regular treatments
Study: NCT05071118
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients received placebo capsules in the ward Then transferred to OR to receive spinal anesthesia before surgery .
Study: NCT05028218
Drug: TQB3824 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB3824 is a CDC7 inhibitor, which plays important roles in the maintenance of DNA replication forks and DNA damage response pathways.
Study: NCT06176196
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets for oral administration.
Study: NCT04712279
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo q.d.for 05 days
Study: NCT06744400
Drug: Grafalon® administered during 5 consecutive days at 1 mg/kg/j
Approvals — FDA: no, EMA: no, PMDA: no
Description: This de-escalation study was planned to investigate 3 doses level of Grafalon® administered during 5 consecutive days, i.e.:~Group 3 : 2 mg/kg/j, Group 2 : 1 mg/kg/j, Group 1 : 0,5 mg/kg/j.~Group 2 receive treatment at lower doses than the recommended dose for the same duration (5 days). Treatment begins on the day of transplantation immediately before the procedure at induction of sedation.
Study: NCT06764862
Drug: HSK44459 dose 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSK44459 taken orally twice daily in the morning and in the evening for 12 weeks.
Study: NCT06764862
Drug: HSK44459 dose 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSK44459 taken orally twice daily in the morning and in the evening for 12 weeks.
Study: NCT06764862
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching HSK44459 taken orally twice daily in the morning and in the evening for 12 weeks.
Study: NCT06531499
Drug: AAA617
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[177Lu\]Lu-PSMA-617 will be administered as an intravenous infusion at a dose of 7.4 GBq (200mCi) (+/- 10%), every 6 weeks for up to 12 cycles.
Study: NCT06531499
Drug: Gonadotropin-releasing hormone (GnRH) analogues
Normalized name: Gonadotropin releasing hormone analogues
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anatomical Therapeutic Chemical \[ATC\] code L02AE
Study: NCT06054321
Drug: antidepressant monotherapy group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the antidepressant monotherapy group, dosage escalation will be determined every 3 weeks.
Study: NCT06702124
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administration for 24 weeks
Study: NCT05899816
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC injection
Study: NCT06764316
Drug: BAY 3547926
Approvals — FDA: no, EMA: no, PMDA: no
Description: antibody conjugate with actinium-225 label
Study: NCT06764316
Drug: BAY 3547922
Approvals — FDA: no, EMA: no, PMDA: no
Description: antibody conjugate without actinium-225 label as preinjection
Study: NCT06379217
Drug: [68Ga]Ga-PSMA-11
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[68Ga\]Ga-PSMA-11 will be administered as a single intravenous dose of approximately 150 MBq (4 mCi) to be administered during baseline imaging and approximately 7 weeks after last RLT dose. Administered dose should not be lower than 111 MBq (3 mCi) or higher than 259 MBq (7 mCi)
Study: NCT06379217
Drug: [68Ga]GA-DOTA-TATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[68Ga\]Ga-DOTA-TATE will be administered as a single intravenous dose to be administered during baseline imaging and approximately 7 weeks after last RLT dose, within a range of 100-200MBq (2.7-5.4 mCi)
Study: NCT06379217
Drug: [68Ga]Ga-NeoB
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[68Ga\]Ga-NeoB will be administered as a single intravenous dose to be administered during baseline imaging and approximately 7 weeks after last RLT dose.within a range of 150-250 MBq (4.1-6.8 mCi).
Study: NCT06379217
Drug: [177Lu]Lu-PSMA-617
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[177Lu\]Lu-PSMA-617 will be administered as an intravenous infusion at a dose of 7.4 GBq (200mCi) (+/- 10%), every 6 weeks for 6 cycles.
Study: NCT06379217
Drug: [177Lu]Lu-DOTA-TATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[177Lu\]Lu-DOTA-TATE will be administered as an intravenous infusion at a dose of 7.4 GBq (200mCi) (+/- 10%) every 6 weeks for 6 cycles.
Study: NCT06379217
Drug: [177Lu]Lu-NeoB
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[177Lu\]Lu-NeoB will be administered as an intravenous infusion at a dose of 9.25 GBq (250mCi) every 6 weeks for 6 cycles
Study: NCT06379217
Drug: L-Lysine HCl-L-Arginine HCl, 2.5 %,
Approvals — FDA: no, EMA: no, PMDA: no
Description: sterile solution for infusion Lysine HCl-Arginine HCl, 2.5 % (1L)
Study: NCT06379217
Drug: Gonadotropin-releasing hormone (GnRH) analogues
Normalized name: Gonadotropin releasing hormone analogues
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anatomical Therapeutic Chemical \[ATC\] code L02AE
Study: NCT06734234
Drug: GSK4771261
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK4771261 will be administered.
Study: NCT06734234
Drug: Placebo matching GSK4771261
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching GSK4771261 will be administered.
Study: NCT06764875
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: BID, oral administration
Study: NCT06766500
Drug: Synjardy® 5 mg/850 mg film-coated tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet of Empagliflozin+Metformin 5 mg/850 mg filmcoated tablets
Study: NCT06105528
Drug: PMN310
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60-minute intravenous infusion
Study: NCT06105528
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60-minute intravenous infusion
Study: NCT05566795
Drug: Chemotherapeutic Agent
Normalized name: Other chemotherapeutics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous solution for injection
Study: NCT05410860
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.
Study: NCT06786676
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of Placebo tablet
Study: NCT06651567
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo rapidly disintegrating tablet, taken once daily, sublingual administration
Study: NCT06744439
Drug: BR1015
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet administered alone
Study: NCT06744439
Drug: BR1015-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet administered alone
Study: NCT06744439
Drug: BR1015-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet administered alone
Study: NCT04846881
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06789302
Drug: DT2-SCT intravenous infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: DT2-SCT is an investigational therapy using autologous adipose-derived mesenchymal stem cells (MSCs) prepared from each participant's adipose tissue. MSCs are isolated from approximately 50 mL of adipose tissue obtained through a tumescent liposuction procedure. The cells are expanded, tested for contaminants, and suspended in a sterile, cryopreservation-free medium (Plasma-Lyte A) for administration.~The intervention involves a single intravenous infusion of DT2-SCT at a dosage of 1 x 10\^6 MSCs/kg body weight, delivered over a period of one hour. Participants will be closely monitored for at least two hours post-infusion to assess immediate safety and potential adverse effects.
Study: NCT06790823
Drug: The probiotic supplement (Moodamin capsuls)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The probiotic supplement (Moodamin capsuls) provided from Amin pharmacytical company, Iran, was freeze-dried containing Lactobacillus helveticus and Bifidobacterium Longum bacteria at a dose of 2.682 × CFU and 0.318 × CFU each capsule, respectively.Excipients include xylitol, maltodextrin, plum flavor, and malic acid.
Study: NCT06790823
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The probiotic supplement (Moodamin capsuls) provided from Amin pharmacytical company, Iran, was freeze-dried containing Lactobacillus helveticus and Bifidobacterium Longum bacteria at a dose of 2.682 × CFU and 0.318 × CFU each capsule, respectively. Excipients include xylitol, maltodextrin, plum flavor, and malic acid. A placebo product used for the control group was made up of excipients only.
Study: NCT06783569
Drug: JR8603
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion on Days 1, 8, and 15 of continuous 28-day cycles
Study: NCT06740903
Drug: inj. lignocaine infusion @1-2 mg/kg/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anesthesia induction will be done by doing pre-oxygenation for 3 minutes with 100% oxygen, propofol 2-2.5 mg/kg intravenous (IV) and nalbuphine 0.1mg/kg intravenous (IV). Tracheal intubation will be facilitated by succinylcholine 1.5 mg/kg IV. Anaesthesia will be maintained with isoflurane 0.6 mac, 60% nitrous oxide, 40% oxygen, atracurium 0.5mg/kg bolus followed by 0.15mg/kg maintenance dose every 30 mints until completion of surgery. Patients Intraoperative monitoring will include electrocardiogram leads II and V5, non-invasive blood pressure at 5 min intervals, oxygen saturation, end-tidal carbon dioxide and nasopharyngeal temperature. Patients will be ventilated by intermittent positive pressure ventilation using a circle system to maintain normocapnia. In group A, patients will be given inj. lignocaine infusion @ 1-2 mg/kg/h intraoperatively
Study: NCT06188208
Drug: VVD-130850
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets
Study: NCT04975295
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT06153693
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily (QD) for 12 weeks
Study: NCT05972772
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 250-mg capsules; Pfizer
Study: NCT06444451
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Injection solution Route of administration: SC injection
Study: NCT06736587
Drug: DWP212525 10mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWP212525 10mg
Study: NCT06736587
Drug: DWP212525 30mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWP212525 30mg
Study: NCT06736587
Drug: DWP212525 50mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWP212525 50mg
Study: NCT06736587
Drug: DWP212525 100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWP212525 100mg
Study: NCT06736587
Drug: DWP212525 200mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWP212525 200mg
Study: NCT06736587
Drug: DWP212525 400mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWP212525 400mg
Study: NCT06736587
Drug: DWP212525 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWP212525 placebo
Study: NCT06452134
Drug: Coenzyme Q10 100 MG Oral Tablet
Normalized name: Coenzyme Q10 100 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coenzyme Q10 oral Tablet with dosage of 100mg daily given for a period of 30 days after surgery.
Study: NCT06772727
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: After preoxygenation with 100% oxygen for 3 minutes, the study drug (fentanyl) will be administered. Patients will receive 1 mcg/kg fentanyl of 10 mcg/mL fentanyl solution (prepared by diluting 100 mcg fentanyl in saline to a total volume of 10 mL).